EOM Pharmaceuticals Holdings, Inc.
IMUC
$0.1388
-$0.0099-6.66%
OTC PK
| 09/30/2022 | 03/31/2022 | 12/31/2021 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 93.04% | -17.52% | -90.51% | -90.51% | 17.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.37% | -20.99% | -69.25% | -69.25% | 20.40% |
| Operating Income | -37.37% | 20.99% | 69.25% | 69.25% | -20.40% |
| Income Before Tax | -52.02% | 22.01% | -116.63% | -116.63% | -21.73% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -52.02% | 22.01% | -116.63% | -116.63% | -21.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -52.02% | 22.01% | -116.63% | -116.63% | -21.73% |
| EBIT | -37.37% | 20.99% | 69.25% | 69.25% | -20.40% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 39.64% | 69.06% | -63.47% | -63.47% | -35.37% |
| Normalized Basic EPS | 40.00% | 69.29% | 76.79% | 76.79% | -34.62% |
| EPS Diluted | 9.91% | 55.16% | -67.93% | -67.93% | -35.37% |
| Normalized Diluted EPS | 40.00% | 69.29% | 76.79% | 76.79% | -34.62% |
| Average Basic Shares Outstanding | 151.29% | 151.29% | 32.48% | 32.48% | -9.85% |
| Average Diluted Shares Outstanding | 151.29% | 151.29% | 32.48% | 32.48% | -9.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |